Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tolterodine + local oestrogens is a combination therapy used primarily for the treatment of overactive bladder (OAB) symptoms in women, particularly those with urinary frequency, urgency, nocturia, and/or urgency urinary incontinence. Tolterodine is a small molecule muscarinic receptor antagonist that reduces involuntary bladder contractions by blocking muscarinic receptors in the detrusor muscle of the bladder. Local oestrogens (such as intravaginal estradiol cream or other topical estrogen formulations) act as hormone replacement therapy to improve urogenital atrophy and may enhance lower urinary tract function by binding to estrogen receptors in urogenital tissues. Clinical studies have shown that both agents individually improve OAB symptoms; combined therapy may provide additional benefit for some patients over longer-term use[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tolterodine + local oestrogens.